Edwards Lifesciences Corp. said it has exercised its option to buy Innovalve Bio Medical Ltd., an early stage transcatheter mitral valve replacemen company, for $300 million in cash following its initial investment in 2017. Since that time, Edwards said Innovalve has demonstrated progress in its program with promising early clinical experience. Read More
Lunglife AI Inc. is looking for a strategic partner to help get Lunglb — its non-invasive test for the early detection of lung cancer — into the market and to the patients who need it. The company’s artificial intelligence-supported blood-based test, which identifies indeterminate lung nodules, will be game changing for early lung cancer diagnosis, Paul Pagano, Lunglife CEO, told BioWorld. Read More
A committee of the U.S. House of Representatives proposed an FDA discretionary spending bill of less than $26 billion in appropriated taxpayer dollars for fiscal year 2025. Read More
The U.S. FDA’s final guidance for device-based treatments for opioid use disorder breaks little new ground relative to the 2023 draft, including a call for the use of a randomized, controlled clinical trial that retains blinding of not just enrollees, but also of the clinicians taking part in these studies. Read More
In June, med-tech deal values saw a modest rise to $93.07 million, up from May's $85.78 million but still lagging behind April's $172.37 million. The monthly average deal value for 2024 has now reached $139.85 million, marking an 84% drop from the 2023 monthly average of $886.13 million. Read More
From no hope to viable treatments, BioWorld is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld team is ‘always on the lookout for what's next.’ Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alzpath, Artelon, Autonomix Medical, Beckman Coulter, Lumicell, RF Innovations, Stryker. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Edwards. Read More
